Loading...
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Dec-24)
₹41.09-0.53%1D
Returns (Since Inception)
24.56%
Rated ★4.5+ on 
Fund Overview
Fund Size
₹5,045 Cr
Expense Ratio
1.09%
ISIN
INF109KC1GH2
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
About this fund
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by ICICI Prudential Mutual Fund. This fund has been in existence for 6 years, 5 months and 6 days, having been launched on 12-Jul-18.
As of 17-Dec-24, it has a Net Asset Value (NAV) of ₹41.09, Assets Under Management (AUM) of 5044.63 Crores, and an expense ratio of 1.09%.
As of 17-Dec-24, it has a Net Asset Value (NAV) of ₹41.09, Assets Under Management (AUM) of 5044.63 Crores, and an expense ratio of 1.09%.
- ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given a CAGR return of 24.56% since inception.
- The fund's asset allocation comprises around 97.27% in equities, 0.00% in debts, and 2.73% in cash & cash equivalents.
- You can start investing in ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+47.75%
+42.13% (Cat Avg.)
3 Years
+26.17%
+20.48% (Cat Avg.)
5 Years
+31.35%
+27.56% (Cat Avg.)
Since Inception
+24.56%
— (Cat Avg.)
Portfolio Summaryas of 30th November 2024
| Equity | ₹4,907.09 Cr | 97.27% |
| Others | ₹137.55 Cr | 2.73% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹721.16 Cr | 14.35% |
| Dr Reddy's Laboratories Ltd | Equity | ₹453.44 Cr | 9.03% |
| Cipla Ltd | Equity | ₹405.25 Cr | 8.07% |
| Lupin Ltd | Equity | ₹230.85 Cr | 4.59% |
| Aurobindo Pharma Ltd | Equity | ₹229.48 Cr | 4.57% |
| Gland Pharma Ltd | Equity | ₹212.15 Cr | 4.22% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹190.75 Cr | 3.80% |
| Treps | Cash - Repurchase Agreement | ₹157.79 Cr | 3.14% |
| Zydus Lifesciences Ltd | Equity | ₹147.08 Cr | 2.93% |
| Divi's Laboratories Ltd | Equity | ₹134.95 Cr | 2.69% |
| Biocon Ltd | Equity | ₹119.96 Cr | 2.39% |
| Medplus Health Services Ltd | Equity | ₹113.82 Cr | 2.27% |
| Shilpa Medicare Ltd | Equity | ₹102.25 Cr | 2.04% |
| AstraZeneca Pharma India Ltd | Equity | ₹98.12 Cr | 1.95% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹97.73 Cr | 1.95% |
| Windlas Biotech Ltd | Equity | ₹95.71 Cr | 1.91% |
| HealthCare Global Enterprises Ltd | Equity | ₹91.35 Cr | 1.82% |
| Fortis Healthcare Ltd | Equity | ₹91.16 Cr | 1.81% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹89.49 Cr | 1.78% |
| Alkem Laboratories Ltd | Equity | ₹81.99 Cr | 1.63% |
| Pfizer Ltd | Equity | ₹77.83 Cr | 1.55% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹75.15 Cr | 1.50% |
| Thyrocare Technologies Ltd | Equity | ₹71.55 Cr | 1.42% |
| Wockhardt Ltd | Equity | ₹70.12 Cr | 1.40% |
| Medi Assist Healthcare Services Ltd | Equity | ₹69.69 Cr | 1.39% |
| Syngene International Ltd | Equity | ₹66.84 Cr | 1.33% |
| FDC Ltd | Equity | ₹65.46 Cr | 1.30% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹64.19 Cr | 1.28% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹61.54 Cr | 1.22% |
| Net Current Assets | Cash | ₹-59.21 Cr | 1.18% |
| Glenmark Life Sciences Ltd | Equity | ₹54.31 Cr | 1.08% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹54.12 Cr | 1.08% |
| Krsnaa Diagnostics Ltd | Equity | ₹53.23 Cr | 1.06% |
| Fine Organic Industries Ltd Ordinary Shares | Equity | ₹52.74 Cr | 1.05% |
| Mankind Pharma Ltd | Equity | ₹52.58 Cr | 1.05% |
| Star Health and Allied Insurance Co Ltd | Equity | ₹44.91 Cr | 0.89% |
| Emcure Pharmaceuticals Ltd | Equity | ₹42.83 Cr | 0.85% |
| Aarti Drugs Ltd | Equity | ₹41.64 Cr | 0.83% |
| Procter & Gamble Health Ltd | Equity | ₹40.82 Cr | 0.81% |
| Blue Jet Healthcare Ltd | Equity | ₹40.28 Cr | 0.80% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹28.44 Cr | 0.57% |
| Alembic Pharmaceuticals Ltd | Equity | ₹24.65 Cr | 0.49% |
| Unichem Laboratories Ltd | Equity | ₹24.28 Cr | 0.48% |
| Hikal Ltd | Equity | ₹19.51 Cr | 0.39% |
| Vinati Organics Ltd | Equity | ₹13.62 Cr | 0.27% |
| Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.17% |
Allocation By Market Cap (Equity)
Large Cap Stocks
40.27%
Mid Cap Stocks
24.96%
Small Cap Stocks
29.36%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹4,805.75 Cr | 95.66% |
| Basic Materials | ₹66.36 Cr | 1.32% |
| Financial Services | ₹44.91 Cr | 0.89% |
Risk & Performance Ratios
Standard Deviation
This fund
14.93%
Cat. avg.
15.68%
Lower the better
Sharpe Ratio
This fund
1.19
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Fund Managers
DK
Dharmesh Kakkad
Since May 2020
SD
Sharmila D’mello
Since July 2022
Additional Scheme Detailsas of 30th November 2024
ISIN INF109KC1GH2 | Expense Ratio 1.09% | Exit Load 1.00% | Fund Size ₹5,045 Cr | Age 6 years 5 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹32.33 Cr | 44.8% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹854.32 Cr | 37.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹854.32 Cr | 35.5% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹42.05 Cr | 40.5% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹217.92 Cr | 46.3% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹217.92 Cr | 43.5% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2742.91 Cr | 40.6% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2742.91 Cr | 38.5% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹840.57 Cr | 36.9% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.39 Cr | 39.6% |
About the AMC
ICICI Prudential Mutual Fund
Total AUM
₹8,87,010 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Other Funds by ICICI Prudential Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth?
The NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth, as of 17-Dec-2024, is ₹41.09.
What are the returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth?
The fund has generated 47.75% over the last 1 year and 26.17% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.
What is the portfolio composition of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth?
The fund's allocation of assets is distributed as 97.27% in equities, 0.00% in bonds, and 2.73% in cash and cash equivalents.
Who manages the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth?
The fund managers responsible for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth are:-
- Dharmesh Kakkad
- Sharmila D’mello
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
©2021-2024 Dezerv. All Rights Reserved
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.